696 related articles for article (PubMed ID: 23867624)
1. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.
Spiekerkoetter E; Tian X; Cai J; Hopper RK; Sudheendra D; Li CG; El-Bizri N; Sawada H; Haghighat R; Chan R; Haghighat L; de Jesus Perez V; Wang L; Reddy S; Zhao M; Bernstein D; Solow-Cordero DE; Beachy PA; Wandless TJ; Ten Dijke P; Rabinovitch M
J Clin Invest; 2013 Aug; 123(8):3600-13. PubMed ID: 23867624
[TBL] [Abstract][Full Text] [Related]
2. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
Yang J; Li X; Al-Lamki RS; Southwood M; Zhao J; Lever AM; Grimminger F; Schermuly RT; Morrell NW
Circ Res; 2010 Jul; 107(2):252-62. PubMed ID: 20522807
[TBL] [Abstract][Full Text] [Related]
3. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
[TBL] [Abstract][Full Text] [Related]
4. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.
Morty RE; Nejman B; Kwapiszewska G; Hecker M; Zakrzewicz A; Kouri FM; Peters DM; Dumitrascu R; Seeger W; Knaus P; Schermuly RT; Eickelberg O
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1072-8. PubMed ID: 17347486
[TBL] [Abstract][Full Text] [Related]
6. Improving Right Ventricular Function by Increasing BMP Signaling with FK506.
Boehm M; Tian X; Ali MK; Mao Y; Ichimura K; Zhao M; Kuramoto K; Dannewitz Prosseda S; Fajardo G; Dufva MJ; Qin X; Kheyfets VO; Bernstein D; Reddy S; Metzger RJ; Zamanian RT; Haddad F; Spiekerkoetter E
Am J Respir Cell Mol Biol; 2021 Sep; 65(3):272-287. PubMed ID: 33938785
[TBL] [Abstract][Full Text] [Related]
7. FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells.
Quist-Løkken I; Andersson-Rusch C; Kastnes MH; Kolos JM; Jatzlau J; Hella H; Olsen OE; Sundan A; Knaus P; Hausch F; Holien T
Cell Commun Signal; 2023 Jan; 21(1):25. PubMed ID: 36717825
[TBL] [Abstract][Full Text] [Related]
8. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
[TBL] [Abstract][Full Text] [Related]
9. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
10. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
[TBL] [Abstract][Full Text] [Related]
11. PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Hennigs JK; Cao A; Li CG; Shi M; Mienert J; Miyagawa K; Körbelin J; Marciano DP; Chen PI; Roughley M; Elliott MV; Harper RL; Bill MA; Chappell J; Moonen JR; Diebold I; Wang L; Snyder MP; Rabinovitch M
Circ Res; 2021 Feb; 128(3):401-418. PubMed ID: 33322916
[TBL] [Abstract][Full Text] [Related]
12. BMPR2 Loss Activates AKT by Disrupting DLL4/NOTCH1 and PPARγ Signaling in Pulmonary Arterial Hypertension.
Awad KS; Wang S; Dougherty EJ; Keshavarz A; Demirkale CY; Yu ZX; Miller L; Elinoff JM; Danner RL
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791441
[TBL] [Abstract][Full Text] [Related]
13. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Long L; Ormiston ML; Yang X; Southwood M; Gräf S; Machado RD; Mueller M; Kinzel B; Yung LM; Wilkinson JM; Moore SD; Drake KM; Aldred MA; Yu PB; Upton PD; Morrell NW
Nat Med; 2015 Jul; 21(7):777-85. PubMed ID: 26076038
[TBL] [Abstract][Full Text] [Related]
14. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
Hong KH; Lee YJ; Lee E; Park SO; Han C; Beppu H; Li E; Raizada MK; Bloch KD; Oh SP
Circulation; 2008 Aug; 118(7):722-30. PubMed ID: 18663089
[TBL] [Abstract][Full Text] [Related]
15. Endothelial
Theilmann AL; Hawke LG; Hilton LR; Whitford MKM; Cole DV; Mackeil JL; Dunham-Snary KJ; Mewburn J; James PD; Maurice DH; Archer SL; Ormiston ML
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2605-2618. PubMed ID: 32998516
[TBL] [Abstract][Full Text] [Related]
16. Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.
Nickel NP; Spiekerkoetter E; Gu M; Li CG; Li H; Kaschwich M; Diebold I; Hennigs JK; Kim KY; Miyagawa K; Wang L; Cao A; Sa S; Jiang X; Stockstill RW; Nicolls MR; Zamanian RT; Bland RD; Rabinovitch M
Am J Respir Crit Care Med; 2015 Jun; 191(11):1273-86. PubMed ID: 25853696
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.
Hwangbo C; Lee HW; Kang H; Ju H; Wiley DS; Papangeli I; Han J; Kim JD; Dunworth WP; Hu X; Lee S; El-Hely O; Sofer A; Pak B; Peterson L; Comhair S; Hwang EM; Park JY; Thomas JL; Bautch VL; Erzurum SC; Chun HJ; Jin SW
Circulation; 2017 Jun; 135(23):2288-2298. PubMed ID: 28356442
[TBL] [Abstract][Full Text] [Related]
18. SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension.
Han C; Hong KH; Kim YH; Kim MJ; Song C; Kim MJ; Kim SJ; Raizada MK; Oh SP
Hypertension; 2013 May; 61(5):1044-52. PubMed ID: 23478097
[TBL] [Abstract][Full Text] [Related]
19. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
[TBL] [Abstract][Full Text] [Related]
20. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension.
Yang X; Long L; Southwood M; Rudarakanchana N; Upton PD; Jeffery TK; Atkinson C; Chen H; Trembath RC; Morrell NW
Circ Res; 2005 May; 96(10):1053-63. PubMed ID: 15845886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
